| Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104: H4 induced haemolytic uraemic syndrome: case-control study J Menne, M Nitschke, R Stingele, M Abu-Tair, J Beneke, J Bramstedt, ... Bmj 345, 2012 | 341 | 2012 |
| Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104: H4 induced haemolytic uraemic syndrome: case-control study J Menne, M Nitschke, R Stingele, M Abu-Tair, J Beneke, J Bramstedt, ... Bmj 345, 2012 | 341 | 2012 |
| Local generation of C-reactive protein in diseased coronary artery venous bypass grafts and normal vascular tissue WJ Jabs, E Theissing, M Nitschke, JFM Bechtel, M Duchrow, S Mohamed, ... Circulation 108 (12), 1428-1431, 2003 | 249 | 2003 |
| Development and validation of a renal risk score in ANCA-associated glomerulonephritis SR Brix, M Noriega, P Tennstedt, E Vettorazzi, M Busch, M Nitschke, ... Kidney international 94 (6), 1177-1188, 2018 | 221 | 2018 |
| Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial O Witzke, IA Hauser, M Bartels, G Wolf, H Wolters, M Nitschke, ... Transplantation 93 (1), 61-68, 2012 | 196 | 2012 |
| Recommendations for the use of rituximab (anti‐CD20 antibody) in the treatment of autoimmune bullous skin diseases§ M Hertl, D Zillikens, L Borradori, L Bruckner‐Tuderman, H Burckhard, ... JDDG: Journal der Deutschen Dermatologischen Gesellschaft 6 (5), 366-373, 2008 | 189 | 2008 |
| Association between azithromycin therapy and duration of bacterial shedding among patients with Shiga toxin–producing enteroaggregative Escherichia coli O104: H4 M Nitschke, F Sayk, C Härtel, RT Roseland, S Hauswaldt, J Steinhoff, ... Jama 307 (10), 1046-1052, 2012 | 179 | 2012 |
| Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the … J Barratt, R Lafayette, J Kristensen, A Stone, D Cattran, J Floege, V Tesar, ... Kidney international 103 (2), 391-402, 2023 | 110 | 2023 |
| Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins I Shimanovich, M Nitschke, C Rose, J Grabbe, D Zillikens British Journal of Dermatology 158 (2), 382-388, 2008 | 108 | 2008 |
| The CD40-CD40L pathway contributes to the proinflammatory function of intestinal epithelial cells in inflammatory bowel disease F Borcherding, M Nitschke, G Hundorfean, J Rupp, D Von Smolinski, ... The American journal of pathology 176 (4), 1816-1827, 2010 | 82 | 2010 |
| Recommendations for the use of immunoapheresis in the treatment of autoimmune bullous diseases D Zillikens, K Derfler, R Eming, G Fierlbeck, M Goebeler, M Hertl, ... JDDG: Journal der Deutschen Dermatologischen Gesellschaft 5 (10), 881-887, 2007 | 79 | 2007 |
| Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial HJL Heerspink, J Radhakrishnan, CE Alpers, J Barratt, S Bieler, U Diva, ... The Lancet 401 (10388), 1584-1594, 2023 | 73 | 2023 |
| Preformed donor-specific HLA antibodies in living and deceased donor transplantation: a multicenter study M Ziemann, W Altermann, K Angert, W Arns, A Bachmann, T Bakchoul, ... Clinical Journal of the American Society of Nephrology 14 (7), 1056-1066, 2019 | 67 | 2019 |
| Slowing the progression of chronic allograft nephropathy by conversion from cyclosporine to tacrolimus: a randomized controlled trial M Meier, M Nitschke, B Weidtmann, WJ Jabs, W Wong, S Suefke, ... Transplantation 81 (7), 1035-1040, 2006 | 67 | 2006 |
| Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: long-term results after 7 years of a randomized clinical trial O Witzke, M Nitschke, M Bartels, H Wolters, G Wolf, P Reinke, IA Hauser, ... Transplantation 102 (5), 876-882, 2018 | 61 | 2018 |
| Bactericidal activity of renal tubular cells: The putative role of human β-defensins M Nitschke, S Wiehl, PC Baer, B Kreft Experimental nephrology 10 (5-6), 332-337, 2002 | 57 | 2002 |
| Improvement of treatment-refractory atopic dermatitis by immunoadsorption: a pilot study M Kasperkiewicz, E Schmidt, Y Frambach, C Rose, M Meier, M Nitschke, ... Journal of Allergy and Clinical Immunology 127 (1), 267-270. e6, 2011 | 55 | 2011 |
| Duration of Fecal Shedding of Shiga Toxin–Producing Escherichia coli O104:H4 in Patients Infected During the 2011 Outbreak in Germany: A Multicenter Study RP Vonberg, M Höhle, M Aepfelbacher, FC Bange, C Belmar Campos, ... Clinical infectious diseases 56 (8), 1132-1140, 2013 | 51 | 2013 |
| Lessons Learned From Outbreaks of Shiga Toxin Producing Escherichia coli S Hauswaldt, M Nitschke, F Sayk, W Solbach, JKM Knobloch Current Infectious Disease Reports 15, 4-9, 2013 | 50 | 2013 |
| Enhanced human β-defensin-2 (hBD-2) expression by corticosteroids is independent of NF-κB in colonic epithelial cells (CaCo2) T Witthöft, CS Pilz, K Fellermann, M Nitschke, EF Stange, D Ludwig Digestive diseases and sciences 50, 1252-1259, 2005 | 45 | 2005 |
